107 related articles for article (PubMed ID: 9337682)
1. Predictive value of serum medroxyprogesterone acetate concentration for response in advanced or recurrent breast cancer.
Nishimura R; Nagao K; Matsuda M; Baba K; Matsuoka Y; Yamashita H; Fukuda M; Higuchi A; Ikeda K
Eur J Cancer; 1997 Aug; 33(9):1407-12. PubMed ID: 9337682
[TBL] [Abstract][Full Text] [Related]
2. An analysis of serum interleukin-6 levels to predict benefits of medroxyprogesterone acetate in advanced or recurrent breast cancer.
Nishimura R; Nagao K; Miyayama H; Matsuda M; Baba K; Matsuoka Y; Yamashita H; Fukuda M; Mizumoto T; Hamamoto R
Oncology; 2000 Aug; 59(2):166-73. PubMed ID: 10971177
[TBL] [Abstract][Full Text] [Related]
3. A randomized controlled comparative study of oral medroxyprogesterone acetate 1,200 and 600 mg in patients with advanced or recurrent breast cancer.
Koyama H; Tominaga T; Asaishi K; Abe R; Iino Y; Enomoto K; Miura S; Nomura Y; Nakazato H; Abe O
Oncology; 1999; 56(4):283-90. PubMed ID: 10343191
[TBL] [Abstract][Full Text] [Related]
4. Steroid hormone receptors and response to high-dose medroxyprogesterone acetate in advanced breast cancer.
Nomura Y; Tashiro H; Hisamatsu K; Shinozuka K
Anticancer Res; 1988; 8(4):647-51. PubMed ID: 2972248
[TBL] [Abstract][Full Text] [Related]
5. A phase II study of medroxyprogesterone acetate in patients with hormone receptor negative metastatic breast cancer: translational breast cancer research consortium trial 007.
Miller KD; Althouse SK; Nabell L; Rugo H; Carey L; Kimmick G; Jones DR; Merino MJ; Steeg PS
Breast Cancer Res Treat; 2014 Nov; 148(1):99-106. PubMed ID: 25257727
[TBL] [Abstract][Full Text] [Related]
6. Oral high-dose medroxyprogesterone acetate treatment for recurrent breast cancer.
Iino Y; Takeo T; Sugamata N; Aoyagi H; Takai Y; Takei H; Ando T; Koibuchi Y; Yokoe T; Ohwada S
Anticancer Res; 1995; 15(3):1061-4. PubMed ID: 7645926
[TBL] [Abstract][Full Text] [Related]
7. Tamoxifen versus high-dose oral medroxyprogesterone acetate as initial endocrine therapy for patients with metastatic breast cancer: a Piedmont Oncology Association study.
Muss HB; Case LD; Atkins JN; Bearden JD; Cooper MR; Cruz JM; Jackson DV; O'Rourke MA; Pavy MD; Powell BL
J Clin Oncol; 1994 Aug; 12(8):1630-8. PubMed ID: 8040675
[TBL] [Abstract][Full Text] [Related]
8. [Effects of high-dose medroxyprogesterone acetate in advanced breast cancer, with special reference to prior endocrine therapy and hormone receptors].
Nomura Y; Tashiro H; Hisamatsu K; Toi M
Gan To Kagaku Ryoho; 1988 Mar; 15(3):513-8. PubMed ID: 2964811
[TBL] [Abstract][Full Text] [Related]
9. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group.
Thigpen JT; Brady MF; Alvarez RD; Adelson MD; Homesley HD; Manetta A; Soper JT; Given FT
J Clin Oncol; 1999 Jun; 17(6):1736-44. PubMed ID: 10561210
[TBL] [Abstract][Full Text] [Related]
10. [A comparative study between low-dose and high-dose medroxyprogesterone acetate (MPA) in the treatment of advanced and recurrent breast cancer--in relation to dose, serum concentration and response. Osaka Breast Cancer Research Group].
Furukawa J; Yayoi E; Takatsuka Y; Aikawa T; Maeura Y; Kobayashi T; Miyauchi K; Kotsuma Y
Gan To Kagaku Ryoho; 1997 May; 24(7):815-21. PubMed ID: 9170519
[TBL] [Abstract][Full Text] [Related]
11. [Chemo-endocrine therapy with high dose medroxyprogesterone acetate for recurrent or advanced breast cancer].
Maeda T; Kubo Y; Sasajima T; Ikeda K; Hirata S; Yamazaki K; Nakajima S
Gan To Kagaku Ryoho; 1993 Nov; 20(14):2165-9. PubMed ID: 8239681
[TBL] [Abstract][Full Text] [Related]
12. Medroxyprogesterone acetate therapy in advanced breast cancer: the predictive value of androgen receptor expression.
Birrell SN; Roder DM; Horsfall DJ; Bentel JM; Tilley WD
J Clin Oncol; 1995 Jul; 13(7):1572-7. PubMed ID: 7602345
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic study of low- versus high-dose medroxyprogesterone acetate (MPA) in women.
Ohtsu T; Fujii H; Wakita H; Igarashi T; Itoh K; Imoto S; Kohagura M; Sasaki Y
Cancer Chemother Pharmacol; 1998; 42(1):1-8. PubMed ID: 9619751
[TBL] [Abstract][Full Text] [Related]
14. Medroxyprogesterone acetate treatment reduces serum interleukin-6 levels in patients with metastatic breast carcinoma.
Yamashita J; Hideshima T; Shirakusa T; Ogawa M
Cancer; 1996 Dec; 78(11):2346-52. PubMed ID: 8941005
[TBL] [Abstract][Full Text] [Related]
15. Medroxyprogesterone acetate addition or substitution for tamoxifen in advanced tamoxifen-resistant breast cancer: a phase III randomized trial. Australian-New Zealand Breast Cancer Trials Group.
Byrne MJ; Gebski V; Forbes J; Tattersall MH; Simes RJ; Coates AS; Dewar J; Lunn M; Flower C; Gill PG; Stewart J
J Clin Oncol; 1997 Sep; 15(9):3141-8. PubMed ID: 9294477
[TBL] [Abstract][Full Text] [Related]
16. Randomized trial of low- versus high-dose medroxyprogesterone acetate in the induction treatment of postmenopausal patients with advanced breast cancer.
Cavalli F; Goldhirsch A; Jungi F; Martz G; MermillodB ; Alberto P
J Clin Oncol; 1984 May; 2(5):414-9. PubMed ID: 6233398
[TBL] [Abstract][Full Text] [Related]
17. High-dose medroxyprogesterone acetate in advanced breast cancer. Clinical and pharmacokinetic study with a combined oral and intramuscular regimen.
Becher R; Miller AA; Höffken K; Gerhold U; Hirche H; Schmidt CG
Cancer; 1989 May; 63(10):1938-43. PubMed ID: 2522811
[TBL] [Abstract][Full Text] [Related]
18. Benefits of Medroxyprogesterone Acetate (MPA) in Advanced or Recurrent Breast Cancer with Higher Serum Concertration.
Nishimura R; Nagao K; Matsuda M; Baba K; Matsuoka Y; Yamashita H; Fukuda M; Higuchi A; Saiki T
Breast Cancer; 1995 Oct; 2(2):133-141. PubMed ID: 11091543
[TBL] [Abstract][Full Text] [Related]
19. [Clinical pharmacokinetics and practical consequences of optimal use of medroxyprogesterone acetate].
Etienne MC; Milano G; Namer M
Bull Cancer; 1993 May; 80(5):431-8. PubMed ID: 8173196
[TBL] [Abstract][Full Text] [Related]
20. Medroxyprogesterone acetate elevation of Nm23-H1 metastasis suppressor expression in hormone receptor-negative breast cancer.
Palmieri D; Halverson DO; Ouatas T; Horak CE; Salerno M; Johnson J; Figg WD; Hollingshead M; Hursting S; Berrigan D; Steinberg SM; Merino MJ; Steeg PS
J Natl Cancer Inst; 2005 May; 97(9):632-42. PubMed ID: 15870434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
